Enrolling
Placebo-controlled randomized trial of tecovirimat in non-hospitalized patients with Mpox: Canadian Feasibility Study
Learn MoreStart-up
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV
Learn MoreReporting
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Learn MoreStart-up
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men
Learn MoreOngoing
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreEnrolling
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreReporting
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy — A Pilot Feasibility Study
Learn MoreOngoing
A randomized controlled, open-label trial examining the efficacy, safety, and tolerability of ablative therapies for high-grade anal dysplasia versus observation alone in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn MoreEnrolling
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men (MSM) – part of HPV-SAVE study.
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
